Approval · Notice of Compliance 5133 · 1995
FIVEASA: Notice of Compliance 5133
Issued September 18, 1995
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5133
- Date
- September 18, 1995
- Company
- Laval Pharma Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Lower gastrointestinal tract anti-inflammatory
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FIVEASA | 02182718 | — |
| FIVEASA | 02182726 | — |
| FIVEASA | 02182653 | — |
| FIVEASA | 02182661 | — |
| FIVEASA | 02182688 | — |
| FIVEASA | 02182696 | — |
Medicinal ingredients
- MESALAZINE 250 MG per TAB
- MESALAZINE 500 MG per TAB
- MESALAZINE 250 MG per SUP
- MESALAZINE 500 MG per SUP
- MESALAZINE 2 G per SUP
- MESALAZINE 4 G per SUP